Guselkumab is an effective, well-tolerated therapy for psoriasis according to phase II results April 2, 2014
LEO-43204 demonstrates efficacy against actinic keratosis in a first-in-human clinical trial March 27, 2014
Shire's candidate for dystrophic epidermolysis bullosa receives FDA orphan drug status March 26, 2014
Phase III results demonstrate noninferiority of tofacitinib to etanercept in psoriasis patients March 25, 2014
RSS